Geron Corp (STU:GON)
€ 3.135 -0.044 (-1.38%) Market Cap: 1.94 Bil Enterprise Value: 1.70 Bil PE Ratio: 0 PB Ratio: 6.91 GF Score: 39/100

Geron Corp at Goldman Sachs Healthcare Conference Transcript

Jun 15, 2023 / 03:40PM GMT
Release Date Price: €2.8 (-5.08%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Great. Well, thank you so much. We've got -- for everyone who's joining us both here and on the webcast, we've got the team from Geron here, Chip Scarlett, CEO. So maybe let's just start with an overview.

John A. Scarlett
Geron Corporation - Chairman of the Board, President & CEO

Yes, love to. Thanks a lot for inviting us. I'm glad to be here and look forward to the next 45 minutes or so. Well, first of all, I think -- let me give a thumbnail sketch of the company for people who don't know us. Geron is focused on telomerase inhibition as a novel approach to the treatment of heme malignancies. Telomerase itself is an enzyme that's constitutively upregulated in malignant hematopoietic stem and progenitor cells. These are the cells that are really responsible for these diseases. And both of our Phase III programs in lower-risk MDS and relapsed and refractory MF currently have kind of an interesting and relatively low competitive intensity and very high unmet needs for new innovative therapies.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot